This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Huntington's disease (HD)	Huntingtin (HTT); ataxia telangiectasia mutated (ATM); protein kinase Cδ (PRKCD); p53	Cell culture studies suggest inhibiting kinases that phosphorylate p53 could help treat HD. In cultured neuronal cells expressing mutant HTT, p53 phosphorylation was greater than that in cells expressing wild-type HTT. In these cells, an inhibitor of ATM or PRKCD, two kinases that phosphorylate p53, decreased apoptosis compared with vehicle. Next steps include testing inhibitors of p53-phosphorylating kinases in mouse models of HD.	Unpatented; licensing status undisclosed	Grison, A. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Oct. 19, 2011; doi:10.1073/pnas.1106198108 Contact: Giannino Del Sal, The Interuniversity Consortium for Biotechnology National Laboratory, Trieste, Italy e-mail: delsal@incib.it
<i>SciBX</i> 4(44); doi:10.1038/scibx.2011.1243 Published online Nov. 10, 2011				